<DOC>
	<DOCNO>NCT02981082</DOCNO>
	<brief_summary>A double-blinded , placebo-controlled study Dimethyl fumarate ( DMF ) 34 Systemic Sclerosis-Pulmonary Hypertension ( SSc‐PAH ) patient . The study determine safety primary outcome variability DMF treat SSc‐PAH ; primary outcome clinical efficacy pilot trial improvement 6‐minute walk distance ( 6MWD ) .</brief_summary>
	<brief_title>Dimethyl Fumarate ( DMF ) Systemic Sclerosis-Associated Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>A double-blinded , placebo-controlled study Dimethyl fumarate ( DMF ) 34 Systemic Sclerosis-Pulmonary Hypertension ( SSc‐PAH ) patient . The study medication add stable background PAH medication ( ) . Subjects dose 24 week , undergo examination every 8 week , finally evaluate 12 week completion treatment . Dosage twice daily oral dos 120mg first 7 day follow maintenance dose 240mg twice day.Participation total 40 week , include 4-week screening period , 24 week drug , safety follow‐up 12 week last dose . The study determine safety primary outcome variability DMF treat SSc‐PAH ; primary outcome clinical efficacy pilot trial improvement 6‐minute walk distance ( 6MWD ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>1 . Signed inform consent prior study‐mandated procedure 2 . Adult patient 18‐80 year age 3 . World Health Organization Group 1 PAH associate scleroderma ( SSc‐PAH ) 4. WHO functional Class II‐III 5 . 6MWD 150 450 meter 6 . Right heart catheterization demonstrate mPAP≥ 25 mmHg PCWP leave ventricular end diastolic pressure ≤15mm Hg pulmonary vascular resistance ≥240 dynes/cm5 ( 3 Wood unit ) within 12 week prior study entry . 7 . ACR define systemic sclerosis 1 . Pulmonary hypertension associate PAH etiology scleroderma PH etiology WHO Group I PAH Pulmonary venous hypertension define PCWP LVEDP &gt; 15 mHg Untreated sleep apnea AHI &gt; 20 SaO2 Nadir &lt; 87 % Chronic thromboembolic disease Sarcoidosis 2 . Participation clinical investigational study within previous 30 day 3 . Moderate severe hepatic impairment ( e.g. , Child‐Pugh Class B C ) 4 . Renal failure define : estimate creatinine clearance &lt; 30 m/min serum creatinine &gt; 2.5 mg/dl 5 . Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal 6 . Systolic blood pressure &lt; 90mmHg 7 . Recently start ( &lt; 8 week prior randomization ) plan cardiopulmonary rehabilitation program base exercise 8 . Pregnant lactate woman 9 . Need HAART therapy 10 . Planned treatment treatment another investigational drug within 1 month prior start 11 . Moderate severe interstitial lung disease , define FVC &lt; 80 % evidence HRCT fibrosis ground glass change involve 30 % lung parenchyma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Systemic Sclerosis , Scleroderma , PAH , Pulmonary Hypertension</keyword>
</DOC>